- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Eosinophilic Oesophagitis (EoE)
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1526KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 359KB)
Budesonide – March 2021
Budesonide: Tablet (orally disintegrating) 1 mg; Jorveza®
Last updated
16 July 2021